- Dose range
- 3 → 14 mg/day
- Route
- Oral tablet, daily, fasted with 4 oz water
- Indication(s)
- Type 2 diabetes (only)
Titration schedule
| Step | Dose | Duration | Notes |
|---|---|---|---|
| 1 | 3 mg/day | 30 days | Starter; not for glycemic control |
| 2 | 7 mg/day | 30+ days | Maintenance option |
| 3 | 14 mg/day | Max | If inadequate response at 7 mg |
Important notes
- This FDA-approved drug dosing chart is intended as a reference for clinicians and patients reviewing protocols, not a substitute for individualized prescriber guidance.
- FDA-approved label dosing.
- Compounded versions, where applicable, must be prepared by a licensed 503A or 503B compounding pharmacy. The April 14, 2026 FDA action restricted salt-form active ingredients.
References
- Rybelsus (oral semaglutide) prescribing information / clinical literature.
- FDA Section 503A Interim Bulk Drug Substances List, updated April 14, 2026.
- USP <797>: Pharmaceutical Compounding — Sterile Preparations.